Ageing Research Reviews最新文献

{"title":"The complex relationship between gut microbiota and Alzheimer’s disease: A systematic review","authors":"Xuan-Peng Zhou ,&nbsp;Luan-Biao Sun ,&nbsp;Wen-Hao Liu ,&nbsp;Wu-Ming Zhu ,&nbsp;Lin-Chun Li ,&nbsp;Xin-Yuan Song ,&nbsp;Jian-Peng Xing ,&nbsp;Shuo-Hui Gao","doi":"10.1016/j.arr.2024.102637","DOIUrl":"10.1016/j.arr.2024.102637","url":null,"abstract":"<div><div>Alzheimer’s disease (AD) is a progressive, degenerative disorder of the central nervous system. Despite extensive research conducted on this disorder, its precise pathogenesis remains unclear. In recent years, the microbiota-gut-brain axis has attracted considerable attention within the field of AD. The gut microbiota communicates bidirectionally with the central nervous system through the gut-brain axis, and alterations in its structure and function can influence the progression of AD. Consequently, regulating the gut microbiota to mitigate the progression of AD has emerged as a novel therapeutic approach. Currently, numerous studies concentrate on the intrinsic relationship between the microbiota-gut-brain axis and AD. In this paper, we summarize the multifaceted role of the gut microbiota in AD and present detailed therapeutic strategies targeting the gut microbiota, including the treatment of AD with Traditional Chinese Medicine (TCM), which has garnered increasing attention in recent years. Finally, we discuss potential therapeutic strategies for modulating the gut microbiota to alleviate the progression of AD, the current challenges in this area of research, and provide an outlook on future research directions in this field.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"104 ","pages":"Article 102637"},"PeriodicalIF":12.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can microbiota gut-brain axis reverse neurodegenerative disorders in human?","authors":"Xingxing Yuan ,&nbsp;Serge Yannick Ouedraogo ,&nbsp;Modou Lamin Jammeh ,&nbsp;Lucette Simbiliyabo ,&nbsp;John Nute Jabang ,&nbsp;Mariam Jaw ,&nbsp;Alansana Darboe ,&nbsp;Yurong Tan ,&nbsp;Ousman Bajinka","doi":"10.1016/j.arr.2025.102664","DOIUrl":"10.1016/j.arr.2025.102664","url":null,"abstract":"<div><div>The trillions of microbial populations residing in the gut have recently shown that they can be used as a remedy for various diseases. The gut microbiota-brain-axis interface is one unique pathway that the microbiota demonstrates its medicinal value. This medicinal value is further seen when there is a decline in gut microbial diversity (dysbiosis). Dysbiosis leads to neurodegenerative disorders (NDDs). The objective of this review is to ascertain the clinical significance of gut microbiota induced therapeutic strategies. While navigating this important area of interest, we will elucidate the research gaps, the prospects and the potential reverse interventions of the studied NDDs. In addition to our previous work, relevant literature published in English were searched and retrieved from the PubMed database. The ‘gut microbiota and Neurodegenerative disorders’ were used as keywords during the search period. The Filters applied are: Abstract, Full text, Meta-Analysis, Randomized Controlled Trial, Reviews, in the last 5 years. The articles were analyzed in our unrelenting quest to make sense of the prospects and research gap in gut microbiota-brain-axis. This chapter is a result of this meticulous work. More convincing data from researches on gut microbiota-brain-axis are required to provide clinical significance including neuroimaging studies. Addressing the structural (pathological footprints) and the functional changes (diseases manifestation) involving gut microbiota-brain-axis require a holistic approach. While the pharmacological therapies such as chemotherapeutic and chemobiotic treatment approaches come with low success rates, non-pharmacological interventions are found to be more useful in reversing NDDs. The inability to detect NDDs at an early stage in their clinical history, makes preventive medicinal approaches the must needed and best intervention strategy. Gut-driven treatments have a lot to offer in the management of refractory neurologic diseases.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"104 ","pages":"Article 102664"},"PeriodicalIF":12.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving landscape of colorectal cancer: Global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990–2050)","authors":"Jiajie Zhou ,&nbsp;Qizhi Yang ,&nbsp;Shuai Zhao ,&nbsp;Longhe Sun ,&nbsp;Ruiqi Li ,&nbsp;Jie Wang ,&nbsp;Liuhua Wang ,&nbsp;Daorong Wang","doi":"10.1016/j.arr.2025.102666","DOIUrl":"10.1016/j.arr.2025.102666","url":null,"abstract":"<div><h3>Background</h3><div>Presently, colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. We provided global, regional, and national estimates of the burden of CRC and their attributable risks from 1990 to 2021, aiming to guide screening, early detection, and treatment strategies, optimize healthcare resource allocation, and facilitate the rational management of burden of CRC.</div></div><div><h3>Methods</h3><div>Using data derived from the Global Burden of Disease database, we estimated the incidence, mortality, and disability-adjusted life years (DALYs) of CRC. The temporal trends of the age-standardized rate of CRC were quantified by calculating the estimated annual percentage changes (EAPC). Deaths from CRC attributable to each risk factor that had evidence of causation with CRC were estimated. CRC's deaths and DALYs was forecast through 2050 by logistic regression with Socio-Demographic Index as a predictor, then multiplying by projected population estimates.</div></div><div><h3>Results</h3><div>Globally, between 1990 and 2021, the incident cases, death cases, and DALYs attributed to CRC have doubled, the age-standardized incidence rate (ASIR) presented a slightly upward tendency, while the age-standardized death rate (ASMR) and the age-standardized DALYs rate (ASDR) exhibited a decreasing trend. From 1990–2021, the ASIR for males has an increased trend, while females presented a downward trend. The ASIR and ASDR of CRC were higher in high and high-middle sociodemographic index (SDI) countries. The ASIR of CRC in 165 countries and territories showed escalating trend. Globally, for males and both sexes combined, diet low in whole grains was the leading risk factor for age-standardized deaths from CRC in 2021. However, among females, diet low in milk was the leading risk factor. We forecast that 2.18 million (1.53–2.94) individuals will death for CRC worldwide by 2050, and the DALYs achieve 41.7 million (29.9–55.4) by 2050.</div></div><div><h3>Conclusion</h3><div>The doubling of incidence counts and mortality cases and the rising ASIR in most countries indicates a significant burden of CRC. Authorities should devise suitable measures to address the increasing burdens, such as optimizing screening programs, enhancing awareness and screening efforts for males, and reducing exposure to modifiable risk factors.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"104 ","pages":"Article 102666"},"PeriodicalIF":12.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why are we not exploring the potential of lower limb muscle power to identify people with sarcopenia?","authors":"Hélio José Coelho-Júnior ,&nbsp;Alejandro Álvarez-Bustos ,&nbsp;Francesco Landi ,&nbsp;Samuel da Silva Aguiar ,&nbsp;Leocadio Rodriguez-Mañas ,&nbsp;Emanuele Marzetti","doi":"10.1016/j.arr.2025.102662","DOIUrl":"10.1016/j.arr.2025.102662","url":null,"abstract":"<div><div>Sarcopenia refers to a neuromuscular disease characterized by age-related declines in muscle mass and function. Since Professor Rosenberg first introduced the concept of sarcopenia in 1989, numerous operational paradigms have been proposed, tested, and validated against negative outcomes. The most recent recommendations advocate that dynapenia, or reduced of muscle strength, should be used alongside low muscle mass for the identification of sarcopenia. This approach is based on the understanding that impairments in muscle strength are a major consequence of muscle failure. However, empirical evidence has yielded conflicting results regarding the ability of current sarcopenia definitions to identify individuals at higher risk of adverse health-related events. Muscle power — the capacity to generate strength rapidly — has emerged as a critical domain of physical performance in old age. Not only does it decline earlier and more drastically than other measures (e.g., muscle strength), but it is also more strongly associated with adverse outcomes. In this view point, we provide an appraisal of muscle power as a more reliable indicator of muscle failure, compared with other measures (e.g., strength), for identifying individuals with sarcopenia in both geriatric and non-geriatric settings. We also discuss major challenges hindering the conduct of meaningful investigations on this subject.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"104 ","pages":"Article 102662"},"PeriodicalIF":12.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strides towards healthy longevity: Harnessing the power of sports and elements of Kathak, an Indian classical dance form through social participation to combat cognitive frailty among older adults","authors":"Abhijeet Singh Dewari,&nbsp;Shivani Chandel","doi":"10.1016/j.arr.2025.102671","DOIUrl":"10.1016/j.arr.2025.102671","url":null,"abstract":"<div><div>Aging brings with it many health issues that can make life challenging. As much of the attention is given to non-communicable diseases, there are others which are slowly becoming a matter of great concern. One such issue is cognitive frailty, which is a high risk factor for dementia, falls, fractures and hospitalization. Though not yet declared a public health concern, it deserves early detection and prevention strategies. As it is reversible if treated on time, there is a need to look into its prevention and cure. Physical activity has proven to be very effective in the treatment of cognitive frailty. This scoping review thus aims to study the impact of physical activity through social participation on cognitive frailty. The authors recommend that focussing on one's muscular fitness through participation in sports and elements of Indian classical dance form like Kathak in groups/ communities can be a very effective way of combating cognitive frailty among older adults.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"105 ","pages":"Article 102671"},"PeriodicalIF":12.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, current states, and challenges of nanomaterials in anti-neuroinflammation: A perspective on Alzheimer’s disease","authors":"Xinyang Hong ,&nbsp;Tongkai Chen ,&nbsp;Yunyun Liu ,&nbsp;Jun Li ,&nbsp;Dongqing Huang ,&nbsp;Kaiyu Ye ,&nbsp;Wanchen Liao ,&nbsp;Yulin Wang ,&nbsp;Mengling Liu ,&nbsp;Ping Luan","doi":"10.1016/j.arr.2025.102669","DOIUrl":"10.1016/j.arr.2025.102669","url":null,"abstract":"<div><div>Alzheimer's disease (AD), an age-related neurodegenerative disease, brings huge damage to the society, to the whole family and even to the patient himself. However, until now, the etiological factor of AD is still unknown and there is no effective treatment for it. Massive deposition of amyloid-beta peptide(Aβ) and hyperphosphorylation of Tau proteins are acknowledged pathological features of AD. Recent studies have revealed that neuroinflammation plays a pivotal role in the pathology of AD. With the rise of nanomaterials in the biomedical field, researchers are exploring how the unique properties of these materials can be leveraged to develop effective treatments for AD. This article has summarized the influence of neuroinflammation in AD, the design of nanoplatforms, and the current research status and inadequacy of nanomaterials in improving neuroinflammation in AD.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"105 ","pages":"Article 102669"},"PeriodicalIF":12.5,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mild Behavioral Impairment and cognitive functions: A systematic review and meta-analysis","authors":"Barbara Blasutto ,&nbsp;Francesco Fattapposta ,&nbsp;Maria Casagrande","doi":"10.1016/j.arr.2025.102668","DOIUrl":"10.1016/j.arr.2025.102668","url":null,"abstract":"<div><div>Mild behavioral impairment (MBI) represents a recently introduced diagnostic concept that focuses on behavioral and personality changes occurring in late life and associated with cognitive decline. Nevertheless, the relationship between these dimensions remains unclear. This systematic review and meta-analysis aim to analyze the relationship between MBI and cognitive functioning. The review process was conducted according to the PRISMA-Statement. Restrictions were made, selecting the studies published in peer-review journals, including at least one cognitive measure and presenting the measurement of MBI. Studies that included participants with neurological disorders, dementia, or psychiatric disorders or that only did a neuroimaging or genetic study were excluded. Twenty-two studies were included in the systematic review, while in the meta-analysis seventeen studies featured data to be included in the analyses. The results were classified according to the following cognitive domains: global cognitive functioning, memory, language, attention executive functions, visuospatial skills, and processing speed. In the quantitative analysis, only global cognitive functioning, executive function, attention, and memory were evaluated. The results of both qualitative and quantitative analysis indicate that individuals with MBI exhibited diminished performance on cognitive tasks when compared to those without MBI symptoms. These results are stronger when evaluating the various domains individually (particularly memory and executive functions) than when a global assessment was made. These findings highlight the potential role of MBI symptoms as early indicators of neurodegenerative processes, reinforcing the necessity for comprehensive assessments that encompass both behavioral and cognitive evaluations. The early detection of these symptoms in prodromal phases can be very useful for the development of non-pharmacological interventions and may provide relevant guidelines for clinicians in the management and diagnosis of neurodegenerative disorders.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"105 ","pages":"Article 102668"},"PeriodicalIF":12.5,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APOE4, Alzheimer’s and periodontal disease: A scoping review","authors":"Catalina Arévalo-Caro ,&nbsp;Marianela Arce Retana ,&nbsp;Sergio Losada Amaya ,&nbsp;Humberto Arboleda ,&nbsp;Xavier Gallart-Palau ,&nbsp;Aida Serra","doi":"10.1016/j.arr.2024.102649","DOIUrl":"10.1016/j.arr.2024.102649","url":null,"abstract":"<div><h3>Objective</h3><div>The ε4 allele of the apolipoprotein E gene (<em>APOE4</em>) is recognized as the primary genetic risk factor for Alzheimer’s disease (AD) and has been associated with chronic inflammatory conditions, such as periodontal disease (PD). PD has been identified as having a potentiating effect that favors the development and progression of AD. This scoping review investigates the potential relationship between PD and AD through <em>APOE4</em>.</div></div><div><h3>Methods</h3><div>The Joanna Briggs Institute methodology and PRISMA guidelines were followed. The search included articles published in PubMed and Embase, focusing on human studies, and excluding case series, in vitro studies, reviews, and animal studies.</div></div><div><h3>Results</h3><div>Among the studies that evaluated the relationship between PD, <em>APOE4</em>, and AD, a correlation was identified between the gingival index and cognitive impairment in <em>APOΕ4</em> carriers. Additionally, higher levels of apolipoprotein E4 were found in the crevicular fluid of patients with both AD and PD, compared to individuals without AD.</div></div><div><h3>Conclusion</h3><div><em>APOE4</em> may link PD and AD through shared genetic variants, inflammatory pathways, and dyslipidemia, involving both peripheral and central pathways. More comprehensive studies are required to ascertain the relationship between PD, AD, and <em>APOE4</em>, and to determine whether these associations are causal or non-causal in nature.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"105 ","pages":"Article 102649"},"PeriodicalIF":12.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rlip76 in ageing and Alzheimer’s disease: Focus on oxidative stress and mitochondrial mechanisms","authors":"Madhuri Bandaru ,&nbsp;Omme Fatema Sultana ,&nbsp;Md Ariful Islam ,&nbsp;Alvir Rainier ,&nbsp;P. Hemachandra Reddy","doi":"10.1016/j.arr.2024.102600","DOIUrl":"10.1016/j.arr.2024.102600","url":null,"abstract":"<div><div>RLIP76 (Rlip), a stress-responsive protein, plays a multifaceted role in cellular function. This protein acts primarily as a glutathione-electrophile conjugate (GS-E) transporter, crucial for detoxifying hazardous compounds and converting them into mercapturic acids. RLIP76 also modulates cytoskeletal motility and membrane plasticity through its role in the Ral-signaling pathway, interacting with RalA and RalB, key small GTPases involved in growth and metastasis. Beyond its ATP-dependent transport functions in various tissues, RLIP76 also demonstrates GTPase Activating Protein (GAP) activity towards Rac1 and Cdc42, with a preference for Ral-GTP over Ral-GDP. Its functions span critical physiological processes including membrane dynamics, oxidative stress response, and mitochondrial dynamics. The protein’s widespread expression and evolutionary conservation underscore its significance. Our lab discovered that Rlip interacts with Alzheimer's disease (AD) proteins, amyloid beta and phosphorylated and induce oxidative stress, mitochondrial dysfnction and synaptic damage in AD. Our <em>in vitro</em> studies revealed that overexpression of Rlip reduces mitochondrial abnormalities. Further, our in vivo studies (Rlip+/- mice) revealed that a partial reduction of Rlip in mice (Rlip+/−), leads to mitochondrial abnormalities, elevated oxidative stress, and cognitive deficits resembling late-onset AD, emphasizing the protein's crucial role in neuronal health and disease. Finally, we discuss the experimental cross-breedings of overexpression of mice Rlip ^TG/TG or Rlip + /- mice with Alzheimer’s disease models – earlyonset 5XFAD, late-onset APPKI and Tau transgenic mice, providing new insights into RLIP76’s role in AD progression and development. This review summarizes RLIP76’s structure, function, and cellular pathways, highlighting its implications in AD and its potential as a therapeutic target.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"103 ","pages":"Article 102600"},"PeriodicalIF":12.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global trends and regional differences in mortality of cardiovascular disease and its impact on longevity, 1980–2021: Age-period-cohort analyses and life expectancy decomposition based on the Global Burden of Disease study 2021","authors":"Xue Xia ,&nbsp;Xue Tian ,&nbsp;Qin Xu ,&nbsp;Yijun Zhang ,&nbsp;Xiaoli Zhang ,&nbsp;Jing Li ,&nbsp;Anxin Wang","doi":"10.1016/j.arr.2024.102597","DOIUrl":"10.1016/j.arr.2024.102597","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the temporal trend in cardiovascular disease (CVD) mortality and its impact on life expectancy (LE) gains across different Socio-demographic Index (SDI) regions.</div></div><div><h3>Methods</h3><div>Cause-specific mortality estimates during 1980–2021 were obtained from the Global Burden of Disease 2021 study. An age-period-cohort (APC) analysis was adopted to estimate the net/local drifts and the age/period/cohort effects of CVD mortality. CVD-specific contributions to LE gains were estimated with Arriaga’s method.</div></div><div><h3>Results</h3><div>The global age-standardized mortality rate of CVD declined remarkably from 416.1 to 235.2 per 100,000 during 1980–2021, with slight increase in the proportion of CVD death to all-cause mortality. The net drift of CVD mortality was −1.25 % per year during 1980–2019, and we observed negative local drifts across all age groups, among which middle-aged individuals experienced more rapid declines in CVD mortality than their younger counterparts. Favorable period and cohort effects were generally noted, particularly in high SDI countries. Globally, CVD mortality improvements accounted for an increase of 2.28 years (38.89 %) in LE at 20 years during 1980–2019, with relative contributions increasing from 15.18 % in low SDI region (mostly intracerebral hemorrhage) to 64.66 % in high SDI countries (mostly ischemic heart disease). Notably, LE gaps between low and high SDI countries further widened over study period, and the corresponding proportion attributable to CVD increased remarkably.</div></div><div><h3>Conclusion</h3><div>Process in reducing CVD mortality contributed to longevity improvements over the past four decades globally, with expanded cardiovascular health disparities across various SDI regions. More attention should be paid to CVD epidemic in low SDI countries to mitigate regional inequalities.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"103 ","pages":"Article 102597"},"PeriodicalIF":12.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142757129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}